Table 4.

Summary of treatment-emergent adverse events that occurred ≥3% in any treatment group

	Pateclizumab	ADA	Placebo
	(n = 86)	(n = 85)	(n = 43)
Pharyngitis	7 (8.1%)	7 (8.2%)	4 (9.3%)
Headache	3 (3.5%)	11 (12.9%)	2 (4.7%)
Urinary tract infection	7 (8.1%)	7 (8.2%)	2 (4.7%)
Hypertension	5 (5.8%)	5 (5.9%)	1 (2.3%)
Nasopharyngitis	4 (4.7%)	4 (4.7%)	3 (7.0%)
Anemia	5 (5.8%)	3 (3.5%)	2 (4.7%)
Diarrhea	2 (2.3%)	5 (5.9%)	3 (7.0%)
Alanine aminotransferase increased	2 (2.3%)	3 (3.5%)	4 (9.3%)
Rheumatoid arthritis	3 (3.5%)	3 (3.5%)	3 (7.0%)
Gastroenteritis	3 (3.5%)	3 (3.5%)	1 (2.3%)

ADA, adalimumab.